Phase 2 Leukaemia Trial, Recruiting NCT06508099 Sponsor: St. Petersburg State Pavlov Medical University Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06508099
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with one of the following blood or bone marrow conditions: acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloproliferative disease, chronic myeloid leukemia, lymphoblastic lymphoma, or myeloma.
  • People whose disease is at a stable or controlled stage, meaning fewer than 5% abnormal cells in the bone marrow and no abnormal cells in the blood at the time of joining, or at least a partial response to treatment for lymphoma-type conditions.
  • People who have a compatible bone marrow donor — either a related donor who is a 10 out of 10 tissue-type match, or an unrelated donor who is a 9 or 10 out of 10 tissue-type match.
  • People aged 18 or older.
  • People without serious ongoing health conditions alongside their blood disorder.

Who may not be able to join:

  • People with severe kidney, liver, or bilirubin (bile) abnormalities beyond certain measured thresholds (confirm with trial site for exact values).
  • People with significant breathing difficulties or a need for supplemental oxygen.
  • People with unstable blood pressure or circulation problems.
  • People with an active bacterial or fungal infection that is not responding to treatment, indicated by elevated inflammation markers in the blood.
  • People whose overall physical functioning is rated below 70% on a standard health scale (known as the Karnofsky index).
  • People who have previously had an allogeneic (donor) stem cell or bone marrow transplant.
  • People with kidney function below a specific measured level (confirm with trial site).
  • People with serious heart conditions, including reduced pumping function, unstable chest pain, severe heart failure, or a certain type of serious heart rhythm problem.
  • People with severely reduced lung function below specific measured thresholds (confirm with trial site).
  • People who are pregnant.
  • People with a physical or mental health condition that would prevent them from being able to read and sign a consent form.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +78123386265

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
St. Petersburg State Pavlov Medical University
Registry
ClinicalTrials.gov
Start date
15 May 2024
Est. completion
1 May 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Cumulative incidence of gastrointestinal acute GVHD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov